SORAFENIB vs VEMURAFENIB

Compare SORAFENIB (sorafenib) and VEMURAFENIB (ZELBORAF) — clinical data, side effects, and patient experiences.

SORAFENIB

sorafenib · Targeted Cancer Therapy

How it works

Targeted Cancer Therapy agent

Approved for

Sorafenib tablets are a kinase inhibitor indicated for the treatment of Unresectable hepatocellular carcinoma(1.1) Locally recurrent or metastatic

progressive

differentiated thyroid carcinoma (DTC) that is refractory to radioactive iodine treatment.

OralTablet

VEMURAFENIB

ZELBORAF · Targeted Cancer Therapy

How it works

12.1 Mechanism of Action Vemurafenib is a low molecular weight, orally available inhibitor of some mutated forms of BRAF serine- threonine kinase, including BRAF V600E. Vemurafenib...

Approved for

2.1 ) ZELBORAF ® is indicated for the treatment of patients with Erdheim- Chester Disease with BRAF V600 mutation. ( 1.2

2.1 ) Limitation of Use: ZELBORAF is not indicated for treatment of patients with wild-type BRAF melanoma ( 2.1

OralTablet

Quick Comparison

SORAFENIBVEMURAFENIB

Drug Class

Targeted Cancer Therapy

Route

Oral

Half-Life

—

FDA Approved

—

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

SORAFENIB

Diarrhea

>10%

Fatigue

1-10%

Rash

1-10%

Decreased Appetite

1-10%

Nausea

1-10%

Weakness

1-10%

High Blood Pressure

1-10%

Fever

0.1-1%

VEMURAFENIB

Rash

>10%

Joint Pain

1-10%

Fatigue

1-10%

Diarrhea

1-10%

Nausea

1-10%

Fever

1-10%

Hair Loss

0.1-1%

Decreased Appetite

0.1-1%

FDA Warnings

SORAFENIB

5) Risk of Impaired Wound Healing: Withhold sorafenib tablets for at least 10 days prior to elective surgery
7) QT Prolongation: Monitor electrocardiograms and electrolytes in patients at increased risk for ventricular arrhythmias
Advise patients of the potential risk to a fetus and to use effective contraception
2 Hemorrhage An increased risk of bleeding may occur following sorafenib tablets administration

VEMURAFENIB

5 WARNINGS AND PRECAUTIONS New Primary Cutaneous Malignancies: Perform dermatologic evaluations prior to initiation of therapy, every 2 months while on therapy, and for up to 6 months following discontinuation of ZELBORAF
Serious Hypersensitivity Reactions including anaphylaxis and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS Syndrome): Discontinue ZELBORAF for severe hypersensitivity reactions
Correct electrolyte abnormalities and control for cardiac risk factors for QT prolongation
7 ) Serious Ophthalmologic Reactions: Monitor for signs and symptoms of uveitis

Clinical Trial Data

No head-to-head clinical studies found for SORAFENIB vs VEMURAFENIB.

SORAFENIB vs VEMURAFENIB: What You Should Know

Key Differences

Both SORAFENIB and VEMURAFENIB belong to the Targeted Cancer Therapy class. While they share a similar mechanism of action, differences in pharmacokinetics, dosing, and side effect profiles may make one more suitable than the other for individual patients.

Safety Considerations

SORAFENIB carries 4 FDA warnings. VEMURAFENIB carries 4 FDA warnings. Patients should discuss all warnings and contraindications with their healthcare provider before starting or switching medications..

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.

Related Comparisons

LORLATINIB vs SORAFENIB→GEFITINIB vs SORAFENIB→LAROTRECTINIB vs SORAFENIB→IBRUTINIB vs SORAFENIB→BRIGATINIB vs SORAFENIB→PAZOPANIB vs SORAFENIB→

Loading comparison data...

SORAFENIB vs VEMURAFENIB

Compare SORAFENIB (sorafenib) and VEMURAFENIB (ZELBORAF) — clinical data, side effects, and patient experiences.

SORAFENIB

sorafenib · Targeted Cancer Therapy

How it works

Targeted Cancer Therapy agent

Approved for

Sorafenib tablets are a kinase inhibitor indicated for the treatment of Unresectable hepatocellular carcinoma(1.1) Locally recurrent or metastatic

progressive

differentiated thyroid carcinoma (DTC) that is refractory to radioactive iodine treatment.

OralTablet

VEMURAFENIB

ZELBORAF · Targeted Cancer Therapy

How it works

12.1 Mechanism of Action Vemurafenib is a low molecular weight, orally available inhibitor of some mutated forms of BRAF serine- threonine kinase, including BRAF V600E. Vemurafenib...

Approved for

2.1 ) ZELBORAF ® is indicated for the treatment of patients with Erdheim- Chester Disease with BRAF V600 mutation. ( 1.2

2.1 ) Limitation of Use: ZELBORAF is not indicated for treatment of patients with wild-type BRAF melanoma ( 2.1

OralTablet

Quick Comparison

SORAFENIBVEMURAFENIB

Drug Class

Targeted Cancer Therapy

Route

Oral

Half-Life

—

FDA Approved

—

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

SORAFENIB

Diarrhea

>10%

Fatigue

1-10%

Rash

1-10%

Decreased Appetite

1-10%

Nausea

1-10%

Weakness

1-10%

High Blood Pressure

1-10%

Fever

0.1-1%

VEMURAFENIB

Rash

>10%

Joint Pain

1-10%

Fatigue

1-10%

Diarrhea

1-10%

Nausea

1-10%

Fever

1-10%

Hair Loss

0.1-1%

Decreased Appetite

0.1-1%

FDA Warnings

SORAFENIB

5) Risk of Impaired Wound Healing: Withhold sorafenib tablets for at least 10 days prior to elective surgery
7) QT Prolongation: Monitor electrocardiograms and electrolytes in patients at increased risk for ventricular arrhythmias
Advise patients of the potential risk to a fetus and to use effective contraception
2 Hemorrhage An increased risk of bleeding may occur following sorafenib tablets administration

VEMURAFENIB

5 WARNINGS AND PRECAUTIONS New Primary Cutaneous Malignancies: Perform dermatologic evaluations prior to initiation of therapy, every 2 months while on therapy, and for up to 6 months following discontinuation of ZELBORAF
Serious Hypersensitivity Reactions including anaphylaxis and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS Syndrome): Discontinue ZELBORAF for severe hypersensitivity reactions
Correct electrolyte abnormalities and control for cardiac risk factors for QT prolongation
7 ) Serious Ophthalmologic Reactions: Monitor for signs and symptoms of uveitis

Clinical Trial Data

No head-to-head clinical studies found for SORAFENIB vs VEMURAFENIB.

SORAFENIB vs VEMURAFENIB: What You Should Know

Key Differences

Safety Considerations

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.